ASCO 2025 | Breast cancer updates at ASCO 2025: SERENA-6, DESTINY-Breast09 & ASCENT-04
Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, provides an overview of recent trials of interest in breast cancer. The Phase III SERENA-6 trial (NCT04964934) demonstrated the benefits of using circulating tumor ctDNA (ctDNA) to guide treatment changes in HR+/HER2- breast cancer, whereas the Phase III DESTINY-Breast09 trial (NCT04784715) showed the superiority of first-line trastuzumab deruxtecan (T-DXd) and pertuzumab in patients with HER2+ breast cancer. The ASCENT-04 trial (NCT05382286) assessed sacituzumab govitecan and pembrolizumab in PD-L1-positive triple-negative breast cancer (TNBC). This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
ASCO 2025 has been a really busy meeting for breast cancer. We’ve seen data from SERENA-6, which just offered an intriguing and interesting way for us to be thinking about whether we’ve achieved clinical utility in that frontline hormone receptor positive setting with utilization of ctDNA testing. We also saw data with antibody conjugates. We saw data with sasituzumab, pembrolizumab in the frontline setting from Ascent04...
ASCO 2025 has been a really busy meeting for breast cancer. We’ve seen data from SERENA-6, which just offered an intriguing and interesting way for us to be thinking about whether we’ve achieved clinical utility in that frontline hormone receptor positive setting with utilization of ctDNA testing. We also saw data with antibody conjugates. We saw data with sasituzumab, pembrolizumab in the frontline setting from Ascent04. We saw data from DESTINY-Breast09 today, which was just looking at the role of HER2, TDXD plus pertuzumab compared to the Cleopatra regimen. And then later today, we’ll also see data just about the oral session and lots of interesting discussions there as well, updates from some important studies with ovarian suppression. And then also whether we can quote unquote have patients deescalate or further right size treatments in the HER2 positive setting. So lots of things that we’ll be talking about after ASCO.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Employment – EQRx (I)
Stock and Other Ownership Interests – EQRx (I)
Consulting or Advisory Role – AstraZeneca; bioTheranostics; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; Gilead Sciences; Lilly; Menarini Silicon Biosystems; Merck; mersana; Mersana; Myovant Sciences; Novartis; Pfizer; Prelude Therapeutics; ProteinQure; Puma Biotechnology; RayzeBio; Regor; Relay Therapeutics; Takeda
Research Funding – Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
